titers were controlled after each ABO-incompatible transfusion using standard laboratory techniques. In the case of O/A recipientdonor blood group constellation we started adsorption of recipients' Anti-A with one or two units of A 2 -RBCs followed by transfusion of A 1 -RBCs with a higher number of A-antigens per RBC. Using the technique of in vivo adsorption of isoagglutinins recipients' anti-A or anti-B titer were reduced thereby allowing a safe infusion of the graft. Of note, Scholl and co-workers [5] reported not only on the lack of severe complications of in vivo adsorption of donor-type RBCs but also on a significant reduction of the demand of RBC transfusion between transplantation and day 30.
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In vivo adsorption of isoagglutinins with donor-type RBCs is easy to perform and is more cost-effective than plasmapheresis. Furthermore, ABO-incompatilbe transfusion in mismatched stem cell transplantation avoids graft manipulation ensuring the quality of an un-manipulated graft.
In the first issue 2016 of Transfusion Medicine And Hemotherapy the transfusion support for ABO-incompatible stem cell transplantation is reviewed [1, 2] . The authors focus on reduction of recipient isoagglutinins by plasmapheresis and red blood cell (RBC) depletion of the graft to avoid immune-hematologic consequences of ABO-incompatible stem cell transplantation. The old, nearly forgotten method of in vivo adsorption of recipient isoagglutinins was cited but not extensively mentioned although it is a simple, low-cost technique to circumvent immediate and delayed hemolysis after ABO-incompatible stem cell transplantation [3] [4] [5] .
Our transfusion/transplant team has successfully performed ABO-incompatible transfusions with donor type RBCs in ABOmajor-incompatible stem cell transplantation up to a recipient isoagglutinin titer of 1: 32. ABO-incompatible RBCs were slowly transfused monitoring vital signs at an intensive care unit. Isoagglutinin
